These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34901391)

  • 21. Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma.
    Kalish SV; Lyamina SV; Usanova EA; Manukhina EB; Larionov NP; Malyshev IY
    Med Sci Monit Basic Res; 2015 Oct; 21():226-34. PubMed ID: 26471744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.
    López González M; van de Ven R; de Haan H; van Eck van der Sluijs J; Dong W; van Beusechem VW; de Gruijl TD
    Clin Exp Immunol; 2020 Aug; 201(2):145-160. PubMed ID: 32301504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.
    Kiyokawa J; Wakimoto H
    Oncolytic Virother; 2019; 8():27-37. PubMed ID: 31750274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.
    Gong Y; Yang J; Wang Y; Xue L; Wang J
    Int J Cancer; 2020 Oct; 147(7):1768-1777. PubMed ID: 32208517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
    Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
    Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites.
    Alfano AL; Nicola Candia A; Cuneo N; Guttlein LN; Soderini A; Rotondaro C; Sganga L; Podhajcer OL; Lopez MV
    Mol Ther Oncolytics; 2017 Sep; 6():31-44. PubMed ID: 28736743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer.
    Zhang J; He T; Yin Z; Shang C; Xue L; Guo H
    Front Oncol; 2022; 12():864021. PubMed ID: 35875098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.
    Rickard BP; Conrad C; Sorrin AJ; Ruhi MK; Reader JC; Huang SA; Franco W; Scarcelli G; Polacheck WJ; Roque DM; Del Carmen MG; Huang HC; Demirci U; Rizvi I
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.
    Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B
    Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
    Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
    Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
    Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
    Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
    Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
    J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
    Qiao J; Dey M; Chang AL; Kim JW; Miska J; Ling A; M Nettlebeck D; Han Y; Zhang L; Lesniak MS
    Oncoimmunology; 2015 Aug; 4(8):e1022302. PubMed ID: 26405578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
    Oh CM; Chon HJ; Kim C
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.
    Reinartz S; Schumann T; Finkernagel F; Wortmann A; Jansen JM; Meissner W; Krause M; Schwörer AM; Wagner U; Müller-Brüsselbach S; Müller R
    Int J Cancer; 2014 Jan; 134(1):32-42. PubMed ID: 23784932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Friend and foe: the regulation network of ascites components in ovarian cancer progression.
    Geng Z; Pan X; Xu J; Jia X
    J Cell Commun Signal; 2023 Sep; 17(3):391-407. PubMed ID: 36227507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.